COVID-19 Antibody Cocktail Sweetens Regeneron’s Growth Story
With REGEN-COV in the mix, Regeneron recorded 51% total revenue growth during Q3, including partnership revenue from Roche, but the product’s long-term viability remains in question.
With REGEN-COV in the mix, Regeneron recorded 51% total revenue growth during Q3, including partnership revenue from Roche, but the product’s long-term viability remains in question.